- Merus N.V. MRUS will highlight interim clinical data on the bispecific antibody petosemtamab (MCLA-158) in previously treated head and neck squamous cell carcinoma (HNSCC) along with the selection of a second abstract on petosemtamab in advanced gastric/esophageal adenocarcinoma at the American Association for Cancer Research (AACR) on April 14-19, 2023.
- The management recently commented that it is looking for a roughly/a little better ORR than double the 13% for Eli Lilly And Co's LLY Erbitux (cetuximab) as meaningfully better.
- Needham analyst says that based on recent conversations with investors, expectations are for an ORR of ~30%.
- At the 2021 Triple meeting data update, the analyst saw 43% ORR for Peto in 7 patients. This response rate is encouraging relative to Merck & Co Inc's MRK Keytruda (16% ORR) or what cetuximab demonstrated in a Phase 2 trial (13%).
- However, the 2021 data was very preliminary, and none of the patients had received prior cetuximab treatment.
- The analyst expects Peto's peak revenue opportunity could be significant and estimates >$1 billion by 2030 in the U.S. (~90k patients w/ Peto getting ~15% market share).
- A positive data update should drive a double-digit upside to the stock.
- Needham holds a Buy rating on the stock with a price target of $33.00.
- Price Action: MRUS shares are down 1.29% at $18.36 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in